Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
immunotherapy |
| gptkbp:administeredBy |
gptkb:physician
|
| gptkbp:approvalYear |
2010
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L03AX17
|
| gptkbp:drugClass |
autologous cellular immunotherapy
|
| gptkbp:genericName |
gptkb:sipuleucel-T
|
| https://www.w3.org/2000/01/rdf-schema#label |
Provenge
|
| gptkbp:indication |
prostate cancer
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Dendreon
|
| gptkbp:mechanismOfAction |
stimulates immune response against prostate cancer cells
|
| gptkbp:notRecommendedFor |
gptkb:women
children |
| gptkbp:prescribes |
adult males
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
gptkb:anemia
fever nausea fatigue headache back pain chills joint ache |
| gptkbp:target |
prostatic acid phosphatase
|
| gptkbp:usedFor |
metastatic castration-resistant prostate cancer
|
| gptkbp:website |
https://www.provenge.com/
|
| gptkbp:bfsParent |
gptkb:Mitchell_H._Gold
gptkb:Dendreon_Pharmaceuticals gptkb:Dendreon gptkb:Dendritic_Cell_Therapy |
| gptkbp:bfsLayer |
7
|